A survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer’s disease

Table 1 Frequencies of survey responses

	Know/want to know	Do not want to know	χ ², df, p value
N	44 (55 %)	36 (45 %)
Interested in a clinical trial	38 (86 %)	26 (72 %)	χ ² = 2.475, df = 1, p = 0.116
50–50 drug-to-placebo randomization
Just as interested	21 (70 %)	14 (58 %)	χ ² = 1.75, df = 2, p = 0.416
Less interested	9 (30 %)	9 (37 %)
No longer interested	0 (0 %)	1 (4 %)
66–33 drug-to-placebo randomization
Just as interested	27 (90 %)	15 (62 %)	χ ² = 5.921, df = 2, p = 0.052
Less interested	2 (7 %)	5 (21 %)
No longer interested	1 (3 %)	4 (16 %)
Open-label extension study
Now be interested	29 (100 %)	23 (96 %)	χ ² = 1.232, df = 1, p = 0.267
Not be interested	0 (0 %)	1 (4 %)

Item responses are presented for those who know or wish to know their genetic mutation status versus those who do not wish to know (percentages represent the proportion of responses for the specific question). For “interested in a clinical trial,” the phrased question asked those who did not want to know their genetic status if they would be willing to learn it to participate in a clinical trial
df degrees of freedom

ISSN: 1758-9193